Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Intracellular deposition of fibrillar aggregates of α-synuclein (αSyn) characterizes neurodegenerative diseases such as Parkinson's disease (PD) and dementia with Lewy bodies.
|
22060133 |
2012 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Therefore, CMA dysfunction mediates aberrant ASYN toxicity, and may be a target for therapeutic intervention in PD and related disorders.
|
19436756 |
2009 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cytoplasmic inclusions containing alpha-synuclein (alpha-Syn) fibrils, referred to as Lewy bodies (LBs), are the signature neuropathological hallmarks of Parkinson's disease (PD).
|
19892735 |
2009 |
Parkinson Disease
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
DOPAL and α-synuclein are both found in dopaminergic neurons, where their levels are elevated in PD and in animal models exposed to chemical toxicants, including agricultural pesticides.
|
31420910 |
2019 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thus, injection of synthetic α-synuclein fibrils into brains of non-transgenic primates induced PD-like α-synuclein pathologies within only 3 months after injection.
|
28148299 |
2017 |
Parkinson Disease
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease.
|
17531291 |
2007 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Abnormal accumulation of alpha-synuclein (alpha-syn) has been linked to several neurological disorders, including Parkinson's disease (PD).
|
17156376 |
2006 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
LHGDN |
Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies.
|
18322396 |
2008 |
Parkinson Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggested that the SNP rs7684318 (T>C) transition of the SNCA gene contributes to PD susceptibility in Chinese Han population, which is consistent with the earlier study form Japan.
|
20513365 |
2010 |
Parkinson Disease
|
0.700 |
AlteredExpression
|
disease |
LHGDN |
Nurr1 was shown to be involved in the regulation of alpha-synuclein, as decreased expression of Nurr1, which has been found in Parkinson's disease patients with Nurr1 mutations, was shown to transcriptionally increase alpha-synuclein expression.
|
18463503 |
2008 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
The loss of RAB39B results in dysregulation of α-synuclein homeostasis and a spectrum of neuropathological features that implicate RAB39B in the pathogenesis of Parkinson disease and potentially other neurodegenerative disorders.
|
25434005 |
2014 |
Parkinson Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Salivary total α-synuclein, oligomeric α-synuclein and SNCA variants in Parkinson's disease patients.
|
27335051 |
2016 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate the formation of oligomeric α-Syn intermediates and reduced axonal mitochondrial transport in human neurons derived from induced pluripotent stem cells (iPSC) from a Parkinson's disease patient carrying an α-Syn gene duplication.
|
29991596 |
2018 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Expression of the human Parkinson-disease-associated protein α-synuclein in all Drosophila neurons induces progressive locomotor deficits.
|
24239353 |
2013 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
α-Synuclein (αSN) aggregation is central to the etiology of Parkinson's disease (PD).
|
30197194 |
2018 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
α-Synuclein (αS) is a major constituent of Lewy bodies, the insoluble aggregates that are the hallmark of one of the most prevalent neurodegenerative disorders, Parkinson's disease (PD).
|
29451381 |
2018 |
Parkinson Disease
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Reduced 5-methylcytosine (5-mC) DNA methylation of α-synuclein has been found in the brains of patients with Parkinson's disease (PD).
|
30557654 |
2019 |
Parkinson Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Association with PD was tested as PARK2 main effect, and in combination with known PD risk factors: SNCA, MAPT, APOE, smoking, and coffee intake.
|
20876472 |
2010 |
Parkinson Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although most patients suffering from PD have a sporadic disease, several genetic causes have been identified in recent years, including alpha-synuclein, parkin, PINK1, dardarin (LRRK2), and DJ-1.
|
17085780 |
2006 |
Parkinson Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Familial Parkinson disease (PD) due to the A30P mutation in the SNCA gene encoding alpha-synuclein is clinically associated with PD symptoms.
|
20437567 |
2010 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson's Disease.
|
31649506 |
2019 |
Parkinson Disease
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Since alterations in synuclein function may predispose to the disease pathology of PD, regardless of the presence of genetic mutations, a more thorough understanding of the cellular regulation and function of alpha-synuclein may be of crucial importance to our understanding of this degenerating disorder.
|
12025860 |
2002 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Because a limited study previously showed that alpha-synuclein (alpha-syn), the major pathogenic protein for Parkinson disease, was expressed in differentiating brain tumors as well as various peripheral cancers, the main objective of the present study was to determine whether alpha-syn might be involved in the regulation of tumor differentiation.
|
17189270 |
2007 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Direct interaction of α-synuclein and AKT regulates IGF-1 signaling: implication of Parkinson disease.
|
21474915 |
2011 |
Parkinson Disease
|
0.700 |
Biomarker
|
disease |
BEFREE |
Examination of her brain revealed alpha-synuclein- and tau-positive inclusions diagnostic of PD and PSP.
|
11935271 |
2002 |